Citigroup reiterated their buy rating on shares of AstraZeneca (LON:AZN) in a research report report published on Monday morning, Digital Look reports. They currently have a GBX 7,000 ($91.47) target price on the biopharmaceutical company’s stock.
Other research analysts have also recently issued reports about the stock. Shore Capital reiterated a buy rating on shares of AstraZeneca in a research note on Tuesday, February 5th. JPMorgan Chase & Co. set a GBX 7,100 ($92.77) target price on shares of AstraZeneca and gave the company a buy rating in a research note on Tuesday, January 29th. Societe Generale boosted their target price on shares of AstraZeneca from GBX 8,400 ($109.76) to GBX 8,500 ($111.07) and gave the company a buy rating in a research note on Wednesday, January 16th. Deutsche Bank reiterated a buy rating and issued a GBX 6,900 ($90.16) target price on shares of AstraZeneca in a research note on Monday, January 14th. Finally, Credit Suisse Group set a GBX 6,350 ($82.97) target price on shares of AstraZeneca and gave the company a buy rating in a research note on Friday, February 15th. Three analysts have rated the stock with a sell rating, six have issued a hold rating and thirteen have issued a buy rating to the company. The stock presently has a consensus rating of Hold and a consensus target price of GBX 6,397.70 ($83.60).
AZN opened at GBX 5,821 ($76.06) on Monday. The company has a debt-to-equity ratio of 179.66, a quick ratio of 0.57 and a current ratio of 0.75. The stock has a market capitalization of $76.36 billion and a price-to-earnings ratio of 30.64. AstraZeneca has a twelve month low of GBX 5,110 ($66.77) and a twelve month high of GBX 6,540 ($85.46).
AstraZeneca Company Profile
AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.
Further Reading: Stock Split
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.